Sanofi buys into Denali’s RIPK1 programme
Sanofi is linking with Denali Therapeutics on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases.
Read More
Tag: DNL747
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
